Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva Inc. is positioned for favorable growth driven by its innovative treatments, particularly Giapreza and Xacduro, which are addressing unmet needs in critical care and infectious disease markets. The company has demonstrated robust revenue momentum, with Xacduro sales projected to escalate from $2.0 million in 2023 to an annualized run rate of $95.3 million by 2025, alongside Giapreza showing consistent sales growth from $14.2 million in 2022 to an anticipated $55.0 million in 2024. Additionally, the company's strong patent protection and lower toxicity profile of its products position Innoviva for sustained commercial success and market competitiveness.

Bears say

Innoviva Inc's portfolio faces significant risks associated with its key healthcare assets, particularly in the context of growing antibiotic resistance impacting its product effectiveness in critical care and infectious disease markets. The company is dependent on the successful commercialization of its products, like ZEVTERA and zoliflodacin, which are challenged by factors such as competition from generics and declining sales for respiratory-focused products, thereby jeopardizing revenue generation. Furthermore, systemic risks, including macroeconomic volatility and potential long-term dilution, exacerbate the uncertainty surrounding Innoviva's financial stability and growth prospects.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.